CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Fluzone® standard IIV3 +1 morebiological
Likely dose
Fluzone® standard IIV3 0.5mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03023176
NCT03023176Phase 4Completed
CompareCT.gov

Protective Mechanisms Against a Pandemic Respiratory Virus: B-cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 5, 2013

Stanford University·interventional·Posted Jan 18, 2017·Updated Apr 21, 2017

In Brief

A Phase 4 clinical trial evaluating Fluzone® standard IIV3 and Fluzone® standard IIV3 Pediatric Dose for Influenza. Completed, enrolled 20 participants.

Detailed Summary

This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
Countries--
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 18, 2017
Enrollment StartSep 1, 2013
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.5 years ago

Interventions

Fluzone® standard IIV3biological

Influenza Virus Vaccine Suspension (0.5ml) for Intramuscular Injection

Fluzone® standard IIV3 Pediatric Dosebiological

Influenza Virus Vaccine Suspension (0.25ml) for Intramuscular Injection